Capital One Financial’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Capital One Financial’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,021	Closed	-$286K	–	151
2021 Q4	$286K	Sell	4,021 -450	-10%	-$32.6K	0.03%	152
2021 Q3	$335K	Hold	4,471	–	–	0.04%	146
2021 Q2	$346K	Sell	4,471 -650	-13%	-$48.3K	0.04%	147
2021 Q1	$378K	Sell	5,121 -1,488	-23%	-$113K	0.05%	136
2020 Q4	$463K	Sell	6,609 -7,200	-52%	-$456K	0.06%	125
2020 Q3	$782K	Hold	13,809	–	–	0.1%	119
2020 Q2	$805K	Hold	13,809	–	–	0.11%	142
2020 Q1	$642K	Buy	+13,809	New	+$720K	0.1%	160

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AWA

Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $938M AUM 29.36% 1-Year Est. Return

Capital One Financial's PBE Position: Q1 2022 in Review

Capital One Financial sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2022, closing a stake of 4,021 shares — an estimated $286K sold.

Capital One Financial first reported a position in PBE in Q1 2020 and held it in 8 quarters. The position peaked at $805K in Q2 2020. 89 funds tracked by Wall St. Rank hold PBE as of Q1 2022.

Capital One Financial reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2022 after selling out during the quarter.
Capital One Financial sold 4,021 Invesco Biotechnology & Genome ETF shares in Q1 2022, an estimated $286K.
Capital One Financial first reported a position in Invesco Biotechnology & Genome ETF in Q1 2020 and held it in 8 quarters.
Capital One Financial's Invesco Biotechnology & Genome ETF position peaked at $805K in Q2 2020.
89 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2022.

Based on Capital One Financial's 13F filing for Q1 2022, filed 13 Apr 2022.